LivaNova Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
LivaNova wird ein jährliches Gewinn- und Umsatzwachstum von 48.1% bzw. 4.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 33.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.7% betragen.
Wichtige Informationen
48.1%
Wachstumsrate der Gewinne
33.7%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 4.4% |
| Zukünftige Eigenkapitalrendite | 7.7% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 12 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 12
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 03LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
Oct 31LivaNova: Economics Should Start Making Sustained Improvements
Oct 18Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Oct 02LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
Aug 21LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
Jul 30At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
Jul 04Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?
Jun 13LivaNova: Focus Is Paying Off
May 12These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong
Apr 08Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?
Feb 05A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)
Jan 15LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry
Dec 25LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company
Nov 29We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 08At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Oct 16Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?
Sep 25Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Jul 26Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?
Jul 03An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued
Jun 09Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital
Apr 13What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
Nov 25Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Oct 29LivaNova Loses Profit Momentum On Higher R&D Expense
Oct 13LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 11FDA labels recall of blood bypass pump systems by LivaNova as most serious
Sep 30Returns On Capital At LivaNova (NASDAQ:LIVN) Have Hit The Brakes
Aug 09LivaNova PLC Non-GAAP EPS of $0.53 beats by $0.01, revenue of $254.2M beats by $4.65M, lowers FY earning guidance
Aug 03Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Jul 19Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,386 | 121 | 299 | N/A | 10 |
| 12/31/2025 | 1,312 | 41 | 476 | N/A | 10 |
| 12/31/2024 | 1,245 | 0 | 729 | N/A | 10 |
| 9/30/2024 | 1,242 | 24 | 109 | 158 | N/A |
| 6/30/2024 | 1,210 | -17 | 85 | 125 | N/A |
| 3/31/2024 | 1,185 | -32 | 30 | 64 | N/A |
| 12/31/2023 | 1,154 | 18 | 40 | 75 | N/A |
| 9/30/2023 | 1,118 | 3 | 8 | 40 | N/A |
| 6/30/2023 | 1,085 | -97 | 29 | 57 | N/A |
| 3/31/2023 | 1,045 | -82 | 36 | 65 | N/A |
| 12/31/2022 | 1,022 | -86 | 43 | 70 | N/A |
| 9/30/2022 | 1,017 | -93 | 60 | 85 | N/A |
| 6/30/2022 | 1,018 | -29 | 51 | 73 | N/A |
| 3/31/2022 | 1,028 | -102 | 86 | 109 | N/A |
| 12/31/2021 | 1,035 | -136 | 77 | 103 | N/A |
| 9/30/2021 | 1,035 | -414 | 82 | 106 | N/A |
| 6/30/2021 | 1,022 | -385 | 59 | 91 | N/A |
| 3/31/2021 | 939 | -417 | 11 | 46 | N/A |
| 12/31/2020 | 934 | -347 | -114 | -79 | N/A |
| 9/30/2020 | 952 | -208 | -150 | -114 | N/A |
| 6/30/2020 | 981 | -161 | -234 | -199 | N/A |
| 3/31/2020 | 1,076 | -102 | -230 | -199 | N/A |
| 12/31/2019 | 1,084 | -158 | -116 | -91 | N/A |
| 9/30/2019 | 1,094 | -222 | -106 | -73 | N/A |
| 6/30/2019 | 1,097 | -260 | 19 | 55 | N/A |
| 3/31/2019 | 1,107 | -211 | 63 | 102 | N/A |
| 12/31/2018 | 1,107 | -178 | 82 | 120 | N/A |
| 9/30/2018 | 1,088 | 0 | 82 | 117 | N/A |
| 6/30/2018 | 1,068 | 33 | N/A | 108 | N/A |
| 3/31/2018 | 1,036 | 59 | N/A | 79 | N/A |
| 12/31/2017 | 1,012 | 54 | N/A | 91 | N/A |
| 9/30/2017 | 795 | 121 | N/A | 114 | N/A |
| 6/30/2017 | 840 | 92 | N/A | 109 | N/A |
| 3/31/2017 | 905 | 55 | N/A | 114 | N/A |
| 12/31/2016 | 965 | 2 | N/A | 90 | N/A |
| 12/31/2015 | 545 | -22 | N/A | -14 | N/A |
| 10/18/2015 | 295 | 14 | N/A | 87 | N/A |
| 7/24/2015 | 301 | 57 | N/A | 80 | N/A |
| 4/24/2015 | 292 | 58 | N/A | 80 | N/A |
| 1/23/2015 | 292 | 66 | N/A | 80 | N/A |
| 10/24/2014 | 288 | 63 | N/A | 75 | N/A |
| 7/25/2014 | 285 | 60 | N/A | 63 | N/A |
| 4/25/2014 | 282 | 55 | N/A | 54 | N/A |
| 1/24/2014 | 276 | 48 | N/A | 61 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: LIVNDas prognostizierte Gewinnwachstum (48.1% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: LIVNDie Erträge des Unternehmens (48.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: LIVNEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: LIVNDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: LIVNDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: LIVNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.7%).